Drugs / ALIS
last change Jan 2026 re-read 2 minutes ago

ALIS

Developed for
pulmonary non-tuberculous mycobacterial infection
Investigated by
Insmed Incorporated

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04677569 Apr 2021 → Nov 2025 pulmonary non-tuberculous mycobacterial infection Insmed Incorporated Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALIS ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677569
Route Inhaled “Inhalation via nebulization over approximately 6 to 15 minutes” NCT04677569